Navigation Links
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
Date:12/9/2008

Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings

PRINCETON, N.J., Dec. 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that a Phase 1 dose escalating study of CPX-351 (cytarabine:daunorubicin) Liposome Injection established the recommended dose for Phase 2 studies and confirmed preliminary observations of safety, enhanced pharmacokinetics and promising anti-tumor activity in patients with advanced leukemia. A final analysis of the Phase 1 data (abstract #2984) and supportive findings from a pre-clinical pharmacodynamic model (abstract #942) were presented at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco.

"In the Phase 1 trial, CPX-351 had a tolerability profile that appears better than conventional cytarabine/daunorubicin treatment and produced impressive anti-leukemic responses, including complete remissions (CRs) at and below the maximum tolerated dose, in relapsed and refractory patients," said Eric J. Feldman, MD, of the Weill Medical College of Cornell University and New York-Presbyterian Hospital, the principal investigator in the study. "These encouraging results suggest that CPX-351 may offer advantages to conventional administration of these commonly used drugs. We are excited to participate in the two Phase 2 studies."

In the study, complete remissions were observed in 11 of 47 patients, including 10 patients (9 CRs and 1 CRp - complete remission without full platelet recovery) of 44 with AML and 1 patient of 3 with acute lymphocytic leukemia (ALL) following treatment with CPX-351. Of the 10 AML CRs, 7 occurred at the two highest dose levels, although complete remissions were achieved at dose levels as little as one third of the maximum tolerated dose (MTD). Of note, 7 CRs were achieved in 22 patient
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
5. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
6. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
7. Memory Pharmaceuticals Receives NASDAQ Decisions
8. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... SALT LAKE CITY, Dec. 17 Dynatronics Corporation (Nasdaq: ... board of directors and the execution of an agreement ... aid in strategic planning and improved corporate profitability. On ... with Vici Capital Partners for consulting services through its ...
... al. released this week and scheduled to be published in ... Medicine , concluded that while screening colonoscopy is associated with ... to deaths from cancer developing in the left side of ... a screening test and clarifies a possible weakness: detecting ...
... Researchers at Thomas Jefferson University have found that ... acoustic neuromas results in better hearing preservation and ... a higher dose of therapy. The study appeared ... Oncology*Biology*Physics . , "We previously had not determined ...
... between facilities also had higher mortality rates, study says ... those lacking insurance, make up the bulk of children ... , The study, published in a recent issue of ... that children who were transferred between hospitals died in ...
... SURGERY,S WORK COMES TO LIFE , , ... surgery. In fact, Maria Siemionow, MD, who performed this country,s ... reconstructive plastic surgeon. Facial transplantation plastic surgery offers great hope ... , "The nation,s first face transplant ...
... A new U.S. study has found that being circumcised ... African American men known to have been exposed to ... clinical trials in Africa, where interventional use of adult ... in heterosexual men. The findings of the new study, ...
Cached Medicine News:Health News:Dynatronics Announces Changes to Board and Launches Operational Improvement Process 2Health News:Annals colonoscopy study underscores importance of quality standards 2Health News:Lower-dose fractionated stereotactic radiotherapy results in better hearing preservation 2Health News:Newborn Hospital Deaths Highest for Those Without Insurance 2Health News:Plastic Surgery Experts Available to Comment on Face Transplant Surgery 2Health News:Circumcision reduces the risk of HIV infection in heterosexual US men 2
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
(Date:12/15/2014)... 2014 Registreer nu via  http://bit.ly/ag8Sypm14de ... 20. Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen ... PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der Aegate ... neue profitablen Unternehmensdienstleistungen, die für Apotheken und ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Abbott (NYSE: ABT ) announced today that it has ... as part of a multi-faceted, company-wide effort to safeguard the ... health care businesses. , In 2007, the company identified energy ... goals to measure its progress. Abbott set out to ...
... EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, ... Application (NDA) to the US Food and Drug Administration ... formulation of cladribine, as a therapy for reducing relapses ... Cladribine Tablets has the potential to be the first ...
Cached Medicine Technology:Abbott Cuts Use of Oil and Coal by 35 Percent 2Abbott Cuts Use of Oil and Coal by 35 Percent 3EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 3EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 4
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
... MRSA is a differential medium designed ... of MRSA. Selective agents are incorporated ... most strains of S. epidermidis and ... substrate resulting in mauve colonies, thus ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
... is equipped with a 180 watt Xenon short arc ... energy transfer from the lamp to the light guide, ... is equivalent to higher watt bulbs. A new IR ... bulb reduces the amount of heat generated from the ...
Medicine Products: